A Randomized Open Label Study to Compare the Bioavailability of Lasmiditan 200 mg Under Fed and Fasted Conditions in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors CoLucid Pharmaceuticals
- 10 Apr 2018 Lilly Completed Acquisition of CoLucid Pharmaceuticals on 1 Mar 2017 and trial got completed in 2015. Hence I have not added Eli Lilly in the associations.
- 19 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Feb 2015 Planned End Date changed from 1 Dec 2014 to 1 Feb 2015, as reported by ClinicalTrials.gov.